The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer.

According to the PPS, the 5-year BCSS was 94.4%, 87.4%, 82.5%, 82.8%, 72.5%, 50.0% for those with stage IB, IIA, IIB, IIIA, IIIB, and IIIC diseases, respectively (P<0.001) ( Figure 3B ), but the survival difference between stage IIB and stage IIIA did not reach statistical significance (P=0.681) We conducted the first multivariate prognostic analyses which adjusted for age, race, histology, tumor grade, T stage, N stage, ER, PR, and HER2 status in addition to PMRT receipt ( Table 3 ).

also in 111,027 other papers